The therapeutic benefits of HMGB1 fragment might be sustained by repeated administration in J2N-k hamsters and further investigation concerning the optimal dose and interval of administration of HMGB1 fragment will be needed for the clinical use of HMGB1 fragment in DCM patients. Here, HMGB1 is linked to familial dilated cardiomyopathy.